Safety and Tolerability of Cannabidivarin (CBDV) in Children and Young Adults With Autism Spectrum Disorder

Summary

To determine the safety and tolerability of GWP42006 (cannabidivarin, CBDV) in children and young adults with autism spectrum disorder (ASD) and to examine the effect of GWP42006 on communication, social interactions, sleep, behavior, and cognition profiles.

Timeline

Start

2020-01-07

Primary completion

2020-05-26

Completion

2020-05-26

Outcome

Outcome not reported

Stopped (Enrollment): “Study terminated due to enrollment challenges during COVID-19 pandemic.”

Drugs

Indications